ReviewESC heart failure2024
The intelligent Impella: Future perspectives of artificial intelligence in the setting of Impella support.
Review in ESC heart failure, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
14 citing papers in PubMed, 1 synthesis or guideline pooled it.
- A Comprehensive Review of Artificial Intelligence (AI) Applications in Pulmonary Hypertension (PH).Medicina (Kaunas, Lithuania) · 2025Pooled it
- Predictors of Bleeding After Percutaneous Left Ventricular Assist Device Support: Findings From the J-PVAD Registry.JACC. Advances · 2026Article
- Can algorithms come to the rescue of a failing heart? Machine learning, artificial intelligence, and decision-making in cardiogenic shock.Journal of anesthesia, analgesia and critical care · 2026Article
- Integration, challenges, and future of artificial intelligence in critical care medicine: comprehensive applications from predictive models to clinical integration.Frontiers in medicine · 2026Review
- An Assessment of ChatGPT's Responses to Common Patient Questions About Lung Cancer Surgery: A Preliminary Clinical Evaluation of Accuracy and Relevance.Journal of clinical medicine · 2025Article
- Reliability, Accuracy, and Comprehensibility of AI-Based Responses to Common Patient Questions Regarding Spinal Cord Stimulation.Journal of clinical medicine · 2025Article
- Language Artificial Intelligence Models as Pioneers in Diagnostic Medicine? A Retrospective Analysis on Real-Time Patients.Journal of clinical medicine · 2025Article
- Key Concepts in Machine Learning and Clinical Applications in the Cardiac Intensive Care Unit.Current cardiology reports · 2025Review
- ChatGPT in cardiovascular medicine: revolution, hype, or helper?Frontiers in public health · 2025Review
- Advancing LVAD Technology: Overcoming Challenges and Shaping the Future of Mechanical Circulatory Support.Journal of clinical medicine · 2024Review
- Use of Intravascular Micro-Axial Left Ventricular Assist Devices as a Bridging Strategy for Cardiogenic Shock: Mid-Term Outcomes.Journal of clinical medicine · 2024Article
- AI driven mechanical circulatory support: Can AI and Impella team up to beat cardiogenic shock.ESC heart failure · 2024Article
- The intelligent Impella: Future perspectives of artificial intelligence in the setting of Impella support.ESC heart failure · 2024Review
- Bridge to Life: Current Landscape of Temporary Mechanical Circulatory Support in Heart-Failure-Related Cardiogenic Shock.Journal of clinical medicine · 2024Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
aimsArtificial intelligence (AI) has emerged as a potential useful tool to support clinical treatment of heart failure, including the setting of mechanical circulatory support (MCS). Modern Impella pumps are equipped with advanced technology (SmartAssist), enabling real-time acquisition and display of data related to both pump performance and the patient's haemodynamic status. These data emerge as an 'ideal' source for data-driven AI applications to predict the clinical course of an ongoing therapeutic protocol. Yet, no evidence of effective application of AI tools in the setting of Impella support is available. On this background, we aimed at identifying possible future applications of AI-based tools in the setting of temporary MCS with an Impella device.
methodsWe explored the state of research and development at the intersection of AI and Impella support and derived future potential applications of AI in routine Impella clinical management.
resultsWe identified different areas where the future implementation of AI tools may contribute to addressing important clinical challenges in the setting of Impella support, including (i) early identification of the best suited pathway of care according to patients' conditions at presentation and intention to treat, (ii) prediction of therapy outcomes according to different possible therapeutic actions, (iii) optimization of device implantation procedures and evaluation of proper pump position over the whole course of support and (iv) prevention and/or rationale management of haemocompatibility-related adverse events. For each of those areas, we discuss the potential advantages, challenges and implications of harnessing AI-driven insights in the setting of MCS with an Impella device.
conclusionsTemporary MCS with an Impella device has great potential to benefit from the integration of AI-based tools. Such tools may indeed translate into groundbreaking innovation supporting clinical decision-making and therapy regulation, in particular in complex scenarios such as the multidevice MCS strategy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.